作者
Hanif Esmail,Nicholas Iain Paton,Jodie Anne Schildkraut,Ilaria Motta,Alexander J. Szubert,Suzanne M. Dufault,Norbert Heinrich,Simon Tiberi,Cissy M Kityo,Timothy Daniel McHugh,Fairoez Ryklief,Daniela María Cirillo,Rodney Dawson,Karen Sanders,Stellah George Mpagama,Lindsay C Thompson,Le Hong Van,Dominic Wakerley,Elena Tudor,Angela M. Crook
摘要
MethodsIn this phase 2, randomized, controlled trial, we assigned participants with rifampin-susceptible pulmonary tuberculosis to receive the standard four-drug combination (isoniazid–rifampin–pyrazinamide–ethambutol; HRZE) for 24 weeks; bedaquiline–delamanid–moxifloxacin for 16 weeks; or one of 10 new four-drug combinations for 16 weeks. The new regimens contained ganfeborole, BTZ-043, or both, with combinations of bedaquiline, delamanid, moxifloxacin, pyrazinamide, pretomanid, and linezolid. The primary end point was the log10(time to positivity) slope (rate of change from baseline to week 12 in the time to Mycobacterium tuberculosis growth in a positive sputum culture). The treatment effect was assessed as the Bayesian posterior probability of superiority of each new regimen to HRZE with respect to the primary end point (results were used to select regimens for further evaluation, rather than for characterization of efficacy). ResultsA total of 401 participants underwent randomization; 371 were included in the modified intention-to-treat population and 400 in the safety population. We identified two promising regimens for further evaluation: ganfeborole–bedaquiline–pretomanid–moxifloxacin (BPMG) and BTZ-043–bedaquiline–delamanid–moxifloxacin (BDMT). The log10(time to positivity) slope was 0.129 log10(days) per week (95% Bayesian credible interval, 0.112 to 0.146) with BPMG and 0.142 log10(days) per week (95% Bayesian credible interval, 0.126 to 0.160) with BDMT, as compared with 0.118 log10(days) per week (95% Bayesian credible interval, 0.105 to 0.131) with HRZE, for a relative difference of 9.1% (95% Bayesian credible interval, −8.6 to 29.0) and 20.5% (95% Bayesian credible interval, 2.7 to 41.1), respectively, and a posterior probability of superiority of 0.83 and 0.99. The incidence of adverse events of grade 3 or higher was 38% in the BPMG group (none of the participants discontinued), 28% in the BDMT group (one discontinued because of a drug reaction with eosinophilia and systemic symptoms), and 24% in the HRZE group (none discontinued). Bedaquiline–moxifloxacin–pyrazinamide–BTZ-043 was discontinued because of hepatotoxic effects. ConclusionsIn this trial, two four-drug regimens, one with ganfeborole and one with BTZ-043, showed evidence of potential efficacy and a safety profile that did not preclude progression to further evaluation. (Funded by Innovative Medicines Initiative 2 Joint Undertaking and others; PARADIGM4TB ClinicalTrials.gov number, NCT06114628.)